Difference between revisions of "Part:BBa K5384001:Design"

 
(→‎References)
Line 16: Line 16:
  
 
===References===
 
===References===
 +
1.Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016).Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73–84.
 +
2.Neuschwander-Tetri, B. A. (2017). Non-alcoholic fatty liver disease. BMC Med. 15(1), 45.Charlton, M. (2004). Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin gastroenterol hepatol. 2, 1048–1058.
 +
3.Vuppalanchi, R., & Chalasani, N. (2009). Nonalcoholic fatty liver disease and nonalco holic steatohepatitis: Selected practical issues in their evaluation and management.Hepatology, 49, 306–317.

Revision as of 14:49, 29 September 2024


Vglycin (Vg)


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

Vglycin has excellent hypoglycemic effect.


Source

vglycin is a 37-amino-acid peptide derived from legumes.

References

1.Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016).Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73–84.

2.Neuschwander-Tetri, B. A. (2017). Non-alcoholic fatty liver disease. BMC Med. 15(1), 45.Charlton, M. (2004). Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin gastroenterol hepatol. 2, 1048–1058. 3.Vuppalanchi, R., & Chalasani, N. (2009). Nonalcoholic fatty liver disease and nonalco holic steatohepatitis: Selected practical issues in their evaluation and management.Hepatology, 49, 306–317.